Coya Therapeutics, Inc.

NASDAQ:COYA

Biotechnology

Healthcare
$3.09 -3.18%

-$0.16 today

Market cap
$72.48M
Beta
0.62
P/E (TTM)
-3.9
EPS (TTM)
-$1.26
52W Low $3.71High $7.75

Volume 0.15M

Average 0.16M

COYA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Coya Therapeutics, Inc.NASDAQ: COYA

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $11M rose 57356.2% year over year, ahead of the +111.9% change in trailing-twelve-month financing cash flow. Sequentially, it fell 46.0% from the prior quarter. Over 3 fiscal years it compounded at +29.6% a year.

Context

  • Financing cash flow amounted to 256.6% of revenue in FY2025, down 194.4 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +57356.2% holds above the trailing-twelve-month pace of +111.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$11M-46.0% QoQ
Last fiscal yearDec 2025
$20.39M+27.2% YoY
LTMMar 2026
$31.36M+111.9% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+57356.2%——
1 year+27.2%——
3-year CAGR+29.6%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
20.39M USD
Year-over-year change
+27.2%

Financing Cash Flow vs competitors

How COYA compares with its peers on the latest reported figures

  • COYA's LTM Mar 2026 financing cash flow of $31.36M is the 7th largest of the 11 companies compared; the peer median is $41.83M.
  • Its year-over-year change of +111.9% is the 6th highest of 10, against a peer median of +1110.6%.
  • Financing cash flow amounts to 395.1% of revenue for COYA, versus a peer median of 2305.2%.
COYA Competitors Peer median
Financing Cash Flow for COYA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OVIDOvid Therapeutics Inc.LTM Mar 2026$164.18M +40238.1%+646.7%2305.2%
IMMXImmix Biopharma, Inc.LTM Mar 2026$107.35M —+221.5%—
WHWKWhitehawk Therapeutics IncLTM Dec 2025$94.38M +72496.9%+9.1%1320.9%
STTKShattuck Labs, Inc.LTM Mar 2026$70.43M +7606.1%+538.8%7043.4%
MGNXMacroGenics, Inc.LTM Mar 2026$69.59M +16083.5%+247.3%44.3%
PLRXPliant Therapeutics, Inc.LTM Mar 2026$32.12M -1858.1%——
COYACoya Therapeutics, Inc.LTM Mar 2026$31.36M +111.9%+29.6%395.1%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$15.14M -54.2%——
CLNNClene Inc.LTM Mar 2026$14.08M +1110.6%-12.6%10506.7%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$5.59M -2029.0%——
CNTXContext Therapeutics Inc.LTM Mar 2026$0 -100.0%-46.9%—
Peer median (excluding COYA) $41.83M+1110.6%+221.5%2305.2%

Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(4.89M)(12.24M)(7.99M)(14.88M)(21.23M)
Depreciation & Amortization16.13K27.36K27.36K27.36K27.36K
Deferred Income Tax399.68K0000
Stock-Based Compensation233.22K207.35K872.25K2.66M4.29M
Change in Working Capital739.17K751.84K(4.64M)1.88M3.88M
Accounts Receivables00(7.5M)7.5M0
Inventory00000
Accounts Payables665.17K845.28K298.82K477.45K(527.01K)
Other Working Capital74K(93.45K)2.56M(6.1M)4.41M
Other Non-Cash Items(399.68K)4.02M543.19K25K2.29M
Operating Cash Flow(3.9M)(7.24M)(11.19M)(10.29M)(10.74M)
Capital Expenditures(136.8K)0000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(525K)(543.19K)(25K)0
Investing Cash Flow(136.8K)(525K)(543.19K)(25K)(1.16M)
Debt Repayment010.47M000
Common Stock Issued1.32K15838.34M14M20.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(341.9K)(1.11M)89.95K2.02M0
Financing Cash Flow(340.58K)9.36M38.43M16.03M20.39M
Effect of Forex Changes00000
Net Change in Cash(4.38M)1.59M26.69M5.71M8.48M
Free Cash Flow(4.04M)(7.24M)(11.19M)(10.29M)(10.74M)

Coya Therapeutics, Inc.

NASDAQ:COYA

Intrinsic Alpha fair value

Locked

Current Price

$3.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.